Macchiarini May Face Involuntary Manslaughter Charges

The embattled stem cell researcher faces a new investigation exploring his culpability in the deaths of two patients he treated.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PIXABAY, DEBORABALVESThe artificial organ researcher who was fired from Sweden’s Karolinska Institute earlier this year has been charged with involuntary manslaughter for the deaths of two of his patients, upon whom he performed artificial trachea transplants, according to Swedish prosecutors. After years of ethical inquiries into his research and clinical practice, Paolo Macchiarini was informed last week of the criminal investigation that may end in formal charges of involuntary manslaughter. The investigation will likely center on two patients Macchiarini treated in the U.S.: one a 2-year-old girl who died in 2013, several months after the procedure; the other, an adult male in Baltimore, who died in 2011, three months after his surgery.

“Of course with the accusations that were made against me last year the prosecutor has to investigate, and I have been very happy to give them any information that they need for that investigation,” Macchiarini told the Associated Press in an email.

If Macchiarini is charged with aggravated involuntary manslaughter, he could face between six months and six years in prison.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo